Molecular mechanism of Activin receptor inhibition by DLK1

D Daniel Antfolk Q Qianqian Ming A Anna Manturova E Erich J. Goebel (Connective Tissue Diseases Therapeutic Focus Area, Regeneron Pharmaceuticals) T Thomas B. Thompson V Vincent C. Luca

Abstract

Abstract Delta-like non-canonical Notch ligand 1 (DLK1) influences myogenesis, adipogenesis, and other aspects of human development through a process that is largely attributed to the downregulation of Notch signaling. Here, we show that DLK1 does not bind to Notch receptors or affect ligand-mediated Notch activation, but instead engages the TGF-β superfamily member Activin receptor type 2B (ACVR2B). The crystal structure of the DLK1-ACVR2B complex reveals that DLK1 mimics the binding mode of canonical TGF-β ligands to compete for access to ACVR2B. In functional assays, DLK1 antagonizes Myostatin-ACVR2B signaling to promote myoblast differentiation, rationalizing a mechanism for the role of DLK1 in muscle development and regeneration. Crosstalk between Notch and TGF-β is mediated by interactions between the transcriptional regulators SMAD2/3 and the Notch intracellular domain (NICD), and DLK1 inhibits SMAD2/3-NICD colocalization. These findings indicate that DLK1 acts directly on ACVR2B to inhibit signaling, whereas the observed effects on Notch may be an indirect result of DLK1 interference with NICD-SMAD complex formation.

Article Details

Volume / Issue Vol. 16, Issue 1
Published July 01, 2025
ISSN 2041-1723
Publisher Nature Portfolio

Journal Info

Nature Communications

Nature Portfolio

ISSN: 2041-1723 Open Access Life Sciences

Authors (6)

D

Daniel Antfolk

Q

Qianqian Ming

A

Anna Manturova

E

Erich J. Goebel

Connective Tissue Diseases Therapeutic Focus Area, Regeneron Pharmaceuticals

T

Thomas B. Thompson

V

Vincent C. Luca